Jeroen M. Tolboom

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

From surplus to scientific value: Repurposing vascular tissues for organ bath standardization to de-risk vasoactive liabilities.

From surplus to scientific value: Repurposing vascular tissues for organ bath standardization to de-risk vasoactive liabilities.

Journal: Journal of pharmacological and toxicological methods
Published: March 02, 2026

A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study.

A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study.

Journal: Nature communications
Published: December 19, 2025

A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines.

A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines.

Journal: EBioMedicine
Published: July 30, 2025

Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infection.

Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infection.

Journal: EBioMedicine
Published: June 26, 2025

Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.

Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.

Journal: EBioMedicine
Published: September 27, 2024

Mosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primates.

Mosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primates.

Journal: NPJ vaccines
Published: April 11, 2024

The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia.

The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia.

Journal: Vaccines
Published: March 15, 2024

Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity.

Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity.

Journal: Scientific reports
Published: November 13, 2023

A replication-incompetent adenoviral vector encoding for HSV-2 gD2 is immunogenic and protective against HSV-2 intravaginal challenge in mice.

A replication-incompetent adenoviral vector encoding for HSV-2 gD2 is immunogenic and protective against HSV-2 intravaginal challenge in mice.

Journal: PloS one
Published: November 08, 2023

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.

Journal: Journal of virology
Published: October 30, 2023

Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in Rabbits.

Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in Rabbits.

Journal: Vaccines
Published: October 25, 2023

Mosaic HIV-1 vaccination induces anti-viral CD8+ T cell functionality in the phase 1/2a clinical trial APPROACH.

Mosaic HIV-1 vaccination induces anti-viral CD8+ T cell functionality in the phase 1/2a clinical trial APPROACH.

Journal: Journal of virology
Published: October 09, 2023
Showing 1-12 of 38

Last Updated: 09/26/2026